Background: Adequate disease and treatment-related risk knowledge of people with Multiple Sclerosis (pwMS) is a prerequisite for informed choices in medical encounters. Previous work showed that MS risk knowledge is low among pwMS and role preferences are different in Italy and Germany.Objective: We investigated the level of risk knowledge and role preferences in 8 countries and assessed putative variables associated with risk knowledge.Methods: An online-survey was performed based on the Risk knowledge questionnaire for people with relapsing-remitting MS (RIKNO 2.0), the electronic Control Preference Scale (eCPS), and other patient questionnaires. Inclusion criteria of participants were: (1) age >= 18 years, (2) a diagnosis of relapsing...
BackgroundMultiple sclerosis (MS) patients are faced with complex risk-benefit profiles of disease-m...
BACKGROUND: People with multiple sclerosis (pwMS) have an increased risk of infections; risk factors...
ABSTRACT More than 700,000 people suffer from multiple sclerosis (MS) in Europe. This implies that ...
Background: Adequate disease and treatment-related risk knowledge of people with Multiple Sclerosis ...
Background: Adequate disease and treatment-related risk knowledge of people with Multiple Sclerosis ...
BackgroundAdequate disease and treatment-related risk knowledge of people with Multiple Sclerosis (p...
BackgroundAdequate disease and treatment-related risk knowledge of people with Multiple Sclerosis (p...
Adequate disease and treatment-related risk knowledge of people with Multiple Sclerosis (pwMS) is a ...
Background: Risk knowledge is relevant to make informed decisions in multiple sclerosis (MS). The ri...
Background Adequate risk knowledge of patients is a prerequisite for shared decision making but few ...
<div><p>Background</p><p>Adequate risk knowledge of patients is a prerequisite for shared decision m...
Background Adequate risk knowledge of patients is a prerequisite for shared decision making but few ...
Background The proportion of people with relapsing-remitting multiple sclerosis prescribed disease m...
OBJECTIVE: To determine tolerance to various risk scenarios associated with current multiple scleros...
Background: High-quality epidemiologic data worldwide are needed to improve our understanding of dis...
BackgroundMultiple sclerosis (MS) patients are faced with complex risk-benefit profiles of disease-m...
BACKGROUND: People with multiple sclerosis (pwMS) have an increased risk of infections; risk factors...
ABSTRACT More than 700,000 people suffer from multiple sclerosis (MS) in Europe. This implies that ...
Background: Adequate disease and treatment-related risk knowledge of people with Multiple Sclerosis ...
Background: Adequate disease and treatment-related risk knowledge of people with Multiple Sclerosis ...
BackgroundAdequate disease and treatment-related risk knowledge of people with Multiple Sclerosis (p...
BackgroundAdequate disease and treatment-related risk knowledge of people with Multiple Sclerosis (p...
Adequate disease and treatment-related risk knowledge of people with Multiple Sclerosis (pwMS) is a ...
Background: Risk knowledge is relevant to make informed decisions in multiple sclerosis (MS). The ri...
Background Adequate risk knowledge of patients is a prerequisite for shared decision making but few ...
<div><p>Background</p><p>Adequate risk knowledge of patients is a prerequisite for shared decision m...
Background Adequate risk knowledge of patients is a prerequisite for shared decision making but few ...
Background The proportion of people with relapsing-remitting multiple sclerosis prescribed disease m...
OBJECTIVE: To determine tolerance to various risk scenarios associated with current multiple scleros...
Background: High-quality epidemiologic data worldwide are needed to improve our understanding of dis...
BackgroundMultiple sclerosis (MS) patients are faced with complex risk-benefit profiles of disease-m...
BACKGROUND: People with multiple sclerosis (pwMS) have an increased risk of infections; risk factors...
ABSTRACT More than 700,000 people suffer from multiple sclerosis (MS) in Europe. This implies that ...